Related Experiment Video

Updated: May 19, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Achieving an early myeloma response in patients with kidney impairment

Stephanie Stringer1, Mark Cook, Paul Cockwell

  • 1School of Immunity and Infection, University of Birmingham, Edgbaston, and Department of Nephrology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom. stephanie.stringer@uhb.nhs.uk

Advances in Chronic Kidney Disease
|August 28, 2012
PubMed

Insights

Treatment for multiple myeloma, especially with severe acute kidney injury, often involves dexamethasone and novel chemotherapy, leading to early responses. However, optimal regimens for patients with kidney impairment require further research due to dosing complexities.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Multiple myeloma treatment, particularly in severe acute kidney injury, shows promising early disease response with dexamethasone and novel chemotherapy agents.
  • Limited evidence exists for optimal chemotherapy regimens in patients with kidney impairment.
  • Drug dosing is complicated by impaired kidney function, affecting treatment choices.

Purpose of the Study:

  • To summarize the current evidence on chemotherapy regimens for multiple myeloma in patients with kidney impairment.
  • To focus on regimens incorporating dexamethasone and novel agents.
  • To identify areas needing further research to improve the evidence base.

Main Methods:

  • Review of current literature on multiple myeloma treatment in patients with kidney impairment.
  • Focus on chemotherapy regimens including dexamethasone and novel agents.
  • Analysis of challenges related to drug dosing and kidney function.

Main Results:

  • Dexamethasone and novel chemotherapy agents are associated with early disease response in most multiple myeloma patients, including those with severe acute kidney injury.
  • Evidence guiding optimal chemotherapy in kidney impairment is limited.
  • Kidney function significantly impacts drug dosing decisions.

Conclusions:

  • Further research is needed to establish optimal chemotherapy regimens for multiple myeloma patients with kidney impairment.
  • Improved evidence is crucial for guiding treatment choices and managing drug dosing in this population.
  • The focus remains on dexamethasone-based regimens and novel agents, with an emphasis on addressing kidney-related complexities.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...